# Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b

> **NCT02339324** · PHASE1 · COMPLETED · sponsor: **Yana Najjar** · enrollment: 31 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Pembrolizumab and high dose interferon alfa-2b (HDI)

## Key facts

- **NCT ID:** NCT02339324
- **Lead sponsor:** Yana Najjar
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-06
- **Primary completion:** 2019-09-01
- **Final completion:** 2019-11-02
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2021-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02339324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02339324, "Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02339324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*